Results 71 to 80 of about 41,075 (183)

HIV‐1 viral load and reservoir size remain stable following SARS‐CoV‐2 mRNA vaccination in people with HIV

HIV Medicine, EarlyView.
Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri, Bianca B Jütte, Jan Vesterbacka, Soo Aleman, Hans‐Gustaf Ljunggren, Marcus Buggert, J Peter Svensson, Anders Sönnerborg, Piotr Nowak   +8 more
wiley   +1 more source

Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study [PDF]

, 2023
Aşılama, devam eden COVID-19 salgını sırasında hastalığın yayılmasını önlemek için temel bir halk sağlığı önlemidir. Konakçının geliştirdiği immün yanıt veya aşının oluşturduğu immünolojik yanıtın devam etmesi, salgının gidişatını değiştirebileceği için ...
Buber, Suleyman, Demirci, Mehmet, Erdem, Mustafa Genco, Kocazeybek, Bekir Sami, Ünlü, Özge   +4 more
core   +2 more sources

Association between obstructive sleep apnea (OSA) and COVID‐19 severity

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Obstructive sleep apnea and sleep‐related hypoxia have been associated with higher rates of hospitalization and mortality among patients with Coronavirus disease 2019 (COVID‐19). We further explored the association between obstructive sleep apnea, COVID‐19 severity and related mortality.
Oria Nassi‐Liberman, Bernice Oberman, Tamar Strahl, Noga Yosef, Dekel Shlomi   +4 more
wiley   +1 more source

Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity [PDF]

, 2023
COVID-19 mRNA vaccines induce protective adaptive immunity against SARS-CoV-2 in most individuals, but there is wide variation in levels of vaccine-induced antibody and T-cell responses.
Collins Mary K., Hirota Masato, Ishikawa Hiroki, Kina Mitsuo, Kitano Hiroaki, Matthews Melissa M., Miyagi Masatake, Miyagi Mio, Mori Tomoari, Sakihara Eishin, Seto Yu, Taira Naoyuki, Tamai Miho, Tamai Osamu, Tamaki Kentaro, Toguchi Sakura, Toma Takeshi, Tomori Hiroaki, Wolf Matthias, Yamashiro Chiaki, Yoshida Makiko, Yukawa Sachie   +21 more
core   +1 more source

The Efficacy of COVID‐19 Vaccination in Mortality Among Multi‐Ethnic Long‐Term Care Residents in New Zealand

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Older adults faced heightened vulnerability during the COVID‐19 pandemic, leading to increased mortality. This study investigated the impact of COVID‐19 vaccination on COVID‐19‐related mortality among the main ethnic groups in long‐term care during the Delta‐Omicron wave in New Zealand.
Gary Cheung, Tony Wu, Kebede Beyene, Amy Hai Yan Chan, Hamish Jamieson, Mataroria Lyndon, Joanna Hikaka, Etuini Ma'u, Brigette Meehan, Xaviour Walker, Claudia Rivera‐Rodriguez   +10 more
wiley   +1 more source

Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study [PDF]

, 2022
The SARS-CoV-2 pandemic led to the development of various vaccines. The BNT162b2 mRNA vaccine was the first approved due to its efficacy in eliciting a humoral immunity response after the second dose. However, a decrease in the antibody concentration was
Alessandra Panico, Antonella De Donno, Antonella Zizza, Chiara Rosato, Floriano Indino, Francesco Bagordo, Giambattista Lobreglio, Michele Chicone, Pietro Alifano, Roberta Lazzari, Tiziana Grassi, Virginia Recchia   +11 more
core   +2 more sources

Innovative γ‐Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery

Small, Volume 22, Issue 26, 8 May 2026.
Identified through multi‐stage selection process, a formulation combining γ‐oryzanol and DLin‐KC2‐DMA, termed as OryKL, demonstrates unique nano‐structural features, highly efficient mRNA transfection and functional integrity during long‐term storage, enables broad biodistribution and distinct cell tropism following intravenous administration with no ...
Pengkai Shi, Haikun Liu, Ahmed Refaat, Hung Nguyen, Anne Nguyen, Kaiting Miao, Yuyang Song, Sylvain Trépout, Rico F. Tabor, Liliana de Campo, Karlheinz Peter, Mark Louis P. Vidallon, Xiaowei Wang   +12 more
wiley   +1 more source

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Frontiers in Immunology, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, Jaimin Patel, Lyndsey M. Muehling, Glenda Canderan, Deborah D. Murphy, Savannah G. Brovero, Samuel M. Ailsworth, Will H. Eschenbacher, Emily C. McGowan, Barbara J. Mann, Michael R. Nelson, Alexandra Kadl, Alexandra Kadl, Judith A. Woodfolk, Thomas A.E. Platts-Mills, Jeffrey M. Wilson   +17 more
doaj   +1 more source

From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function

Advanced Healthcare Materials, Volume 15, Issue 16, 24 April 2026.
The evolution of lipid nanoparticles (LNPs) spans from RNA‐LNPs, used in mRNA vaccines, to DNA‐LNPs, ideal for gene therapies. Emerging bionano architectures, decorated with DNA and plasma proteins, pave the way for advanced DNA‐based therapies that are more stable, targeted, and customizable.
Erica Quagliarini, Daniela Pozzi, Giulio Caracciolo   +2 more
wiley   +1 more source

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study [PDF]

, 2022
Background: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective. Nevertheless, immunocompromised participants were excluded from randomized controlled clinical trials.
Angelis, Carmine De, Arpino, Grazia, Barraco, Chiara, Bianco, Roberto, Buonaiuto, Roberto, Giannatiempo, Rosa, Giuliano, Mario, Iervolino, Anna, Pietroluongo, Erica, Placido, Pietro De, Schettini, Francesco, Tafuro, Margherita, Vozzella, Emilia Anna   +12 more
core   +3 more sources